Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Raven biotechnologies and CMC Icos Biologics have entered into an agreement under which CMC Icos will create a production cell line for Raven's anti-cancer drug candidate, RAV18.
Subscribe to our email newsletter
RAV18 is a humanized antibody targeting the ADAM9 protein on cells. ADAM9 is expressed on many solid tumors and is thought to contribute to disease progression and metastasis. Raven is targeting 2009 for an investigational new drug application (IND) filing of RAV18.
George Schreiner, CEO of Raven, said: “We are delighted to be advancing RAV18 toward an IND filing next year through our relationship with CMC Icos. RAV18 is claimed to be the second IND candidate to come from Raven’s proprietary discovery platform, and the first to target solid tissue cancer stem cells.”